TMO EPM / Hemato H9J
Episodes
69 - Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
11 Mar 2026
Contributed by Lukas
Discussão do artigo: "Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials&q...
68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
11 Jan 2026
Contributed by Lukas
Discussão do artigo: "Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphobla...
67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
07 Jan 2026
Contributed by Lukas
Discussão do artigo: "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With ...
66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
30 Dec 2025
Contributed by Lukas
Discussão do artigo: "Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 stud...
65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
05 Nov 2025
Contributed by Lukas
Discussão do artigo: "Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma" de Wang M JCO 2025Apresentado por: Dra....
64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
02 Nov 2025
Contributed by Lukas
Discussão do artigo: "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin" de Curtis DJ NEJM 2025Apresentado por: ...
63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
01 Sep 2025
Contributed by Lukas
Discussão do artigo: "Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT" de DeFilipp Bl...
62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation
10 Aug 2025
Contributed by Lukas
Discussão do artigo: "Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cel...
61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
04 Aug 2025
Contributed by Lukas
Discussão do artigo: "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Y...
60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
27 Jul 2025
Contributed by Lukas
Discussão do artigo: "Nivolumab-AVD Versus BrentuximabVedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826...
59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
23 Jul 2025
Contributed by Lukas
Discussão do artigo: "Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation&q...
58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study
13 Jul 2025
Contributed by Lukas
Discussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-b...
57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults
06 Jul 2025
Contributed by Lukas
Discussão do artigo: "A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults" de Khandelw...
56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
29 Jun 2025
Contributed by Lukas
Discussão do artigo: "Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities" de Kater A NEJM...
55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
22 Jun 2025
Contributed by Lukas
Discussão do artigo: "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation" de Stone R NEJM 2017Apresentado por: ...
54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
02 Jun 2025
Contributed by Lukas
Discussão do artigo: "Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymp...
53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
02 May 2025
Contributed by Lukas
Discussão do artigo: "Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma&qu...
52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
29 Apr 2025
Contributed by Lukas
Discussão do artigo: "Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia" de Chalandon Y Blood 20...
51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
13 Apr 2025
Contributed by Lukas
Discussão do artigo: "Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia" de Brown J NEJM 2025Apresentado por: Dra....
50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
07 Apr 2025
Contributed by Lukas
Discussão do artigo: "Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia" de Roddie C NEJM 2024Apresentado por: Dr...
49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
18 Mar 2025
Contributed by Lukas
Discussão do artigo: "Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation" de...
48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
16 Mar 2025
Contributed by Lukas
Discussão do artigo: "Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma" de Cohen Y NEJM 2025Apresentado por: Dr. Ma...
47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
11 Mar 2025
Contributed by Lukas
Discussão do artigo: "Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma" de Dimopoulos M NEJM 2024Apresenta...
46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
29 Dec 2024
Contributed by Lukas
Discussão do artigo: "Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study" de Badros...
45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
26 Dec 2024
Contributed by Lukas
Discussão do artigo: "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Facon T NEJM 2024 Apresentado por: Dra. Marce...
44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML
23 Dec 2024
Contributed by Lukas
Discussão do artigo: "Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML" de Rollig C JCO 2...
43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
27 Nov 2024
Contributed by Lukas
Discussão do artigo: "Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma" de Herrera AF NEJM 2024 Apresentado por: Dra. Aline Guerra Discu...
42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)
23 Nov 2024
Contributed by Lukas
Discussão do artigo: "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (H...
41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease
01 Nov 2024
Contributed by Lukas
Discussão do artigo: "An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease" de Kas...
40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
27 Sep 2024
Contributed by Lukas
Discussão do artigo: "Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission" de Shadman M Blood cancer...
39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
25 Sep 2024
Contributed by Lukas
Discussão do artigo: "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between U...
38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
19 Sep 2024
Contributed by Lukas
Discussão do artigo: "Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma" de Hungria V NEJM 2024 Apresentado por: ...
37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
24 Aug 2024
Contributed by Lukas
Discussão do artigo: "Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults" de Litzow MR NEJM 2024 Apresentado por: Dr. ...
36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
16 Aug 2024
Contributed by Lukas
Discussão do artigo: "Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma" de Melani C NEJM 2024 Apresentado por: Dr...
35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
05 Aug 2024
Contributed by Lukas
Discussão do artigo: "A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leuke...
34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
27 Jul 2024
Contributed by Lukas
Discussão do artigo: "Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission &...
33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
14 Jul 2024
Contributed by Lukas
Discussão do artigo: "Asciminib in Newly Diagnosed Chronic Myeloid Leukemia" de Hochhaus A NEJM 2024 Apresentado por: Dra. Camila Frade D...
32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial
12 Jul 2024
Contributed by Lukas
Discussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma&q...
31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial
05 Jul 2024
Contributed by Lukas
Discussão do artigo: "Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or po...
30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE)
03 Jul 2024
Contributed by Lukas
Discussão do artigo: "Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy...
29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT
27 May 2024
Contributed by Lukas
Discussão do artigo: "Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT" de San...
28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
24 Apr 2024
Contributed by Lukas
Discussão do artigo: "Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial&q...
27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
14 Apr 2024
Contributed by Lukas
Discussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma&q...
26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
06 Apr 2024
Contributed by Lukas
Discussão do artigo: "Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3&...
25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors
28 Mar 2024
Contributed by Lukas
Discussão do artigo: "PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA ...
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
25 Mar 2024
Contributed by Lukas
Discussão do artigo: "Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 stud...
23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up
16 Mar 2024
Contributed by Lukas
Discussão do artigo: "Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relap...
22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention
03 Mar 2024
Contributed by Lukas
Discussão do artigo: "Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease preventi...
21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
29 Feb 2024
Contributed by Lukas
Discussão do artigo: "Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticost...
20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
17 Feb 2024
Contributed by Lukas
Discussão do artigo: "Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML" de Short N...
19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
04 Feb 2024
Contributed by Lukas
Discussão do artigo: "Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ...
18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
29 Jan 2024
Contributed by Lukas
Discussão do artigo: "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Sonneveld P NEJM 2023 Apresentado...
17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
14 Jan 2024
Contributed by Lukas
Discussão do artigo: "Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease" de Munir t NEJM 2023. Apresentado por: ...
16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML
17 Dec 2023
Contributed by Lukas
Discussão do artigo: "Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML" de Grob t Clin Oncol 41:756-765. Apres...
15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation
03 Dec 2023
Contributed by Lukas
Discussão do artigo: "Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoi...
14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
26 Nov 2023
Contributed by Lukas
Discussão do artigo: "BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase II...
13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
19 Nov 2023
Contributed by Lukas
Discussão do artigo: "R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma" de Chamuleau MED Lancet Haemat...
12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
13 Nov 2023
Contributed by Lukas
Discussão do artigo: "PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation" de Al-Ho...
11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)
22 Oct 2023
Contributed by Lukas
Discussão do artigo: "Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)" de Costa L, Lancet H...
10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
08 Oct 2023
Contributed by Lukas
Discussão do artigo: "Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma" de Rodriguez‐Otero P, N Engl J Med 2023;...
09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis
02 Oct 2023
Contributed by Lukas
Discussão do artigo: "Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycoph...
08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
24 Sep 2023
Contributed by Lukas
Discussão do artigo: "Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL" de Tisi...
07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients
28 Aug 2023
Contributed by Lukas
Discussão do artigo: "Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of old...
06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
19 Aug 2023
Contributed by Lukas
Discussão do artigo: "Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma" de Jason R. Westin, N Engl J Med 2023; 389:148-157 Apresentado ...
05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3
12 Aug 2023
Contributed by Lukas
Discussão do artigo: "Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leuk...
04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3
05 Aug 2023
Contributed by Lukas
Discussão do artigo: "Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruct...
03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
29 Jul 2023
Contributed by Lukas
Discussão do artigo: "Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Place...
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
21 Jul 2023
Contributed by Lukas
Discussão do artigo: "Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase II...
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
16 Jul 2023
Contributed by Lukas
Discussão do artigo "Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia" de ...